Bibliothek
Finden Sie hier ein Literaturverzeichnis aller Medien, die auf dem eCampus zu finden sind.
- Ellingson BM, Bendszus M, Boxerman J. et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015;17(9):1188–1198.
- Elster AD Questions and answers in MRI. 2023 (accessed 24 April 2023)
- Fink JR, Muzi M, Peck M et al. Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. J Nucl Med. 2015;56(10):1554–1561.
- Johnson DR et al. A Radiologist’s Guide to the 2021 WHO Central Nervous System Tumor Classification: Part I-Key Concepts and the Spectrum of Diffuse Gliomas. Radiology. 2022;304(3):494–508.
- Linn J et al. Tumoren und tumorähnliche Erkrankungen. Atlas Klinische Neuroradiologie des Gehirns. Springer, Berlin. 2011;(1).
- Lipton ML. Totally Accessible MRI. A User’s Guide to Principles, Technology, and Applications. Springer, New York, NY. 2008.
- Osborn A et al. Neoplasien, Zysten und tumorähnliche Läsionen. Osborn’s Brain. Urban & Fischer in Elsevier, München. 2019;(2):449–820.
- Weishaupt D et al. Wie funktioniert MRI? Eine Einführung in Physik und Funktionsweise der Magnetresonanzbildgebung. Springer Berlin, Heidelberg. 2014.
- Die MRT-Bilder stammen aus dem Klinikum rechts der Isar der Technischen Universität München. Die Patient:innen haben in die Verwendung der Bilder zu diesem Zwecke eingewilligt.
- Nieuwenhuys R, Jan Voogd J, van Huijzen C. Das Zentralnervensystem des Menschen: Ein Atlas mit Begleittext. Springer Berlin, Heidelberg. 1991;2cd edition
Glas M. Glioblastom: Aktuelle Konzepte zu Diagnose, Therapie und TTFields. UNI-MED Science, 1. Auflage 2025, ISBN: 978-3-8374-1679-4
- Jiapaer, S., et al. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurol Med Chir (Tokyo). 2018;58(10):405-421.
- Weller, M. and E. Le Rhun. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev. 2020;87:102029.
- Nikolova, T., et al. Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. Biochim Biophys Acta Rev Cancer. 2017;1868(1):29-39.
- Wirsching, H.G., E. Galanis, and M. Weller. Glioblastoma. Handb Clin Neurol. 2016;134:381-97.
- Herrlinger, U., et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678-688.
- Wheeler GP, Bowdon BJ, Struck RF. Carbamoylation of amino acid, peptides, and proteins by nitrosoureas. Cancer Res. 1975;35:2974–84.
- Friendlander, A.H. and R.L. Ettinger. Karnofsky performance status scale. Spec Care Dentist. 2009;29(4):147-8.
- Mischel, A.M. and D.A. Rosielle. Eastern Cooperative Oncology Group Performance Status #434. J Palliat Med. 2022;25(3):508-510.
- Stupp, R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.
- Hofer S et al. Gliome im Erwachsenenalter, 2021 in: Onkopedia. Abgerufen am 08. April 2025.
- Novocure® EU User Manuals
- Gelbe Liste, Wirkstoff Temozolomid. Abgerufen am 30.05.2025.
- US Department of Health and Human Services (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Institutes of Health, National Cancer Institute. Abgerufen am 11. April 2025.
- Wick W et al. Gliome, S2k-Leitlinie, 2021. in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Abgerufen am 08. April 2025.
- Gelbe Liste, Wirkstoff Lomustin. Abgerufen am 30.05.2025.
- Aronin, P.A., et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med. 1980;303(4):183-8.
- Wen, P.Y., et al. RANO 2.0.: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol. 2023;41(33):5187-5199.
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology®. Central Nervous System Cancers (Version 5.2024). Abgerufen am 08. April 2025.
- Park Y, Kc N, Paneque A, Cole PD. Tau Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases. Int J Mol Sci. 2024 Jun 7;25(12):6295.
- Choate KA et al. IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications. Biology. 2024; 13(11), 885.
- Louis DN et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251
- Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000 Mar;182(3):311-22.
- (2006). Immunhistochemie. In: Histotechnik. Springer, Vienna.
- Choate KA et al. IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications. Biology. 2024;13(11):885.
- Alzial G et al. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Onkogen. 2022;41:613–621.
- Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765–73.
- Mauch-Mücke K, Pohl S, Riemenschneider MJ. Hirntumordiagnostik: Neue Entwicklungen und Zukunftsperspektiven Trillium Diagnostik. 2022(1).
- Weller M et al. Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker? Clin Cancer Res. 2007;13(23): 6933–6937.
- Capper, D., Stichel, D., Sahm, F. et al. Praktische Umsetzung der DNA-Methylierung und der Kopienzahlen-basierten ZNS-Tumordiagnostik: die Heidelberg-Erfahrung. Acta Neuropathol. 2018; 136:181–210.
- Gutin PH, Wong ET. Noninvasive Application of Alternating Electric Fields in Glioblastoma: A Fourth Cancer Treatment Modality. Am Soc Clin Oncol Educ Book. 2012;32:126–131.
- Swanson KD et al. An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma. Curr Neurol Neurosci Rep. 2016;16(1):8.
- Kirson ED et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288–3295.
- Kirson ED et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007;104(24):10152–10157.
- Giladi M et al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046.
- Gera N et al. Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit. PLoS One. 2015 May 26;10(5):e0125269.
- Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044–1054.
- Cooper GM. The Cell: A Molecular Approach. 2. Auflage. Sinauer Associates; 2000:chap 15. Abgerufen am 08. April 2025.
- Baba Al, Câtoi C. Tumor cell morphology. In: Comparative Oncology. The Publishing House of the Romanian Academy; 2007:chap 3. Abgerufen am 08. April 2025
- Trainito CI et al. Characterization of sequentially-staged cancer cells using electrorotation. PLoS One. 2019;14(9):1–18.
- Haemmerich D et al. Electrical conductivity measurement of excised human metastatic liver tumours before and after thermal ablation. Physiol Meas. 2009;30(5):459–466.
- Ahmad MA et al. Electrical Characterization of Normal and Cancer Cells. IEEE Access. 2018;6:25979–25986.
- Stupp R et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306–2316.
- Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–1280.
- Toms SA et al. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467–473.
- Lacouture ME et al. Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. Front Oncol. 2020;10:1045.
- Wick W et al. Gliome, S2k-Leitlinie, 2021. in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Abgerufen am 08. April 2025.
- Hofer S et al. Gliome im Erwachsenenalter, 2021 in: Onkopedia. Abgerufen am 08. April 2025.
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology®. Central Nervous System Cancers (Version 5.2024). Abgerufen am 08. April 2025.
- Novocure® EU User Manuals
- Mrugala MM et al. Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022. J Neurooncol. 2024;169:25–38.
- Ballo MT et al. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. J Neurooncol. 2023; 164(1):1–9.
- Ebert N, Gani C. DNA-Reparaturhemmung in der Strahlentherapie. Onkologe. 2022;(28):135–140.
- O’Driscoll M, Jeggo PA. The role of double-strand break repair – insights from human genetics. Nat Rev Genet. 2006;7(1):45–54.
- Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008;15(7):1153–62.
- Ross GM. Induction of cell death by radiotherapy. Endocr Relat Cancer. 1999;6(1):41–4.
- Stimpson KM, Matheny JE, Sullivan BA. Dicentric chromosomes: unique models to study centromere function and inactivation. Chromosome Res. 2012;20(5):595–605.
- Barra V, Fachinetti D. The dark side of centromeres: types, causes and consequences of structural abnormalities implicating centromeric DNA. Nat Commun. 2018;9(1):4340.
- Adamietz I. Perkutane Strahlentherapie in der Tumorbehandlung. Onkologe. 2018;(24):263–276.
- Baumann R. et al. Strahlen für das Leben. Im Auftrag der DEGRO (Deutsche Gesellschaft für Radioonkologie e.V.). Haase Druck GmbH, 2021.